Merck Discontinues MK-3682B, MK-3682C Development Programs For HCV Infection - Nasdaq

Merck Discontinues MK-3682B, MK-3682C Development Programs For HCV Infection Nasdaq (RTTNews.com) - Merck ( MRK ) announced Friday its strategic decision to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of ... and more »

from Health - Google News http://ift.tt/2ywNxto